DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for testicular granulosa cell tumor — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTesticular granulosa cell tumor maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for testicular granulosa cell tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
catenin beta 1 (CTNNB1) — CTNNB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet prodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8Z10 · 2.35 Å · ligand PROLINE (PRO). Experimental structure, not a prediction.
What the evidence adds up to
Juvenile granulosa cell tumour of the testis is extremely rare in childhood and is considered benign because metastasis has never been reported. A 2008 case report of a newborn with unilateral scrotal swelling was confirmed by histopathology and immunohistochemistry; follow-up at six months after surgery showed no recurrence. The authors note that although the tumour is very rare, it is an important differential diagnosis for a newborn scrotal mass. A 2020 review states that in males it represents the most frequent congenital testicular neoplasm, with the vast majority of cases occurring in the perinatal period, presenting as a scrotal or abdominal mass and more often affecting the left testis. Approximately 20% of patients have ambiguous external genitalia. Metastases have not been reported.
Adult-type testicular granulosa cell tumour is also quite rare, as described in a 2012 case report that focused on radiological findings. No survival data, response rates, or sample sizes beyond single cases are provided in these abstracts. The 2020 review notes that in females the tumour occurs predominantly in the first three decades of life, presents unilaterally as stage I disease in the vast majority of cases, and the majority of cases have a good prognosis.
Testicular-sparing surgery is the recommended treatment for the juvenile type. No drug therapy is mentioned in any of these abstracts. There is no evidence from these reports of any systemic treatment, chemotherapy, or repurposed drug being tested for testicular granulosa cell tumour.
What is still missing is any prospective or comparative trial data, any study of drug intervention, any patient stratification beyond age and sex, and any funding for research into systemic therapy for the vanishingly small number of cases where surgery is not sufficient or where adult-type tumours might behave differently.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Perinatology · 2008 · 23 citations
Juvenile Granulosa Cell Tumor of Testis: Case Report and Review of Literature
AbstractJuvenile granulosa cell tumor (JGCT) of testis is extremely rare in childhood. It is considered a benign entity because metastasis has never been reported. Testicular-sparing surgery is the recommended treatment. We reported this case in a newborn who presented with unilateral scrotal swelling. Histopathology and immunohistochemistry confirmed JGCT. Follow-up at 6 months after surgery did not show any recurrence. Even though JGCT is very rare in childhood, it is one of the important differentials of newborn scrotal mass.
Adult-type testicular granulosa cell tumor: a case report and radiological findings of a rare testicular tumor
AbstractWe report a case of an adult-type testicular granulosa cell tumor and the radiological findings of this rare tumor. Authors: Kobayashi, Ko; Itoh, Naoki; Sakai, Shigeru; Sato, Masaaki Corresponding Author: Kobayashi, Ko Abstract Among testicular neoplasms, adult-type testicular granulosa cell tumors are quite rare. We report a case of an adult-type testicular granulosa cell […]
AbstractA granulosa cell tumor occurring in the ovary and testis.In females it occurs predominantly in the first three decades of life and presents unilaterally as stage I disease in the vast majority of cases.It is characterized by the presence of granulosa cells forming macrofollicular structures.T he majority of cases have a good prognosis.In males it represents the most frequent congenital testicular neoplasm and the vast majority of cases occur in the perinatal period.It presents as a scrotal or abdominal mass and it more often affects the left testis.Approximately 20% of the patients have ambiguous external genitalia.It is characterized by the presence of cystic spaces lined by granulosa cells and cells resembling theca cells.Metastases have not been reported.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
